LQDA Liquidia Inc.: Enterprise Value to EBITDA Ratio
Litigation and liquidity shortages are driving volatility, which is reflected in the EV/EBITDA multiple of the core business for Liquidia Corporation (LQDA). Meanwhile, the value of 16.79 shows the most recent value of the metric. The company's foundation is based on its authority in pulmonary hypertension therapy and the use of unique drug delivery systems, which allow it to maintain pricing power for innovative inhalation products.
Comprehensive metric breakdowns and analytics for liquidia.com (LQDA)
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
- financial results and valuation multiples details:
LQDA - Net Profit|Projected Future Earnings Liquidia Corporation|LQDA - Business Payback Period|Forward P/E Multiple Liquidia Corporation|LQDA - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Liquidia Inc.|LQDA - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Liquidia|LQDA - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months liquidia.com|LQDA - Earnings per share increase in current year|Earnings growth forecast for next year Liquidia Corporation
- company sales and revenue statistics:
Summary company analytics:Liquidia Technologies LQDA
To objectively assess the fundamental quality of Liquidia Corporation (LQDA), investors must compare the total enterprise value with its operating profit before interest, taxes, depreciation, and amortization. The EV/EBITDA trend demonstrates the stability of cash flows, which is critical for Liquidia Corporation (LQDA) amid prolonged patent disputes that could radically alter the market value of assets and operational efficiency.
Analysis of competing companies
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Haleon Group HLN|Kenvue Health (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|jyongbio.com - Enterprise Value to Operating Income Before Depreciation Ratio|LGND: EV/EBITDA Multiple|Amneal Pharmaceuticals, Inc. - Business Value to Operating Income Before Depreciation|PRGO (Perrigo Company) - EV/EBITDA Multiple|Company Value to EBITDA Alvotech Biopharmaceuticals ALVO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Galapagos NV (GLPG)|ANIP (anipharmaceuticals.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MannKind MNKD|Amphastar Pharmaceuticals Inc - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Pacira - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio ARS Corp SPRY|Theravance Biopharma (TBPH) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Multiple aquestive.com AQST|Enterprise Value to EBITDA Ratio SCPH|EV/EBITDA Multiple Tectonic|EV/EBITDA Multiple TNXP|Total Company Value to Operating Income Before Depreciation Ratio sxtchina.com|EV/EBITDA Multiple EPRX (Eupraxia Pharmaceuticals Inc.)|BHST: Enterprise Value to Operating Income Before Depreciation|eXoZymes - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Oramed Pharmaceuticals ORMP|ENTX: EV/EBITDA Multiple|MindWalk Therapeutics (HYFT) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio ABVC|CPIX: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple QNTM|Enterprise Value to EBITDA Ratio FibroGen Inc FGEN|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Telomir Pharma TELO|Rani Therapeutics Holdings (RANI) - Company Value to EBITDA|SNYR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation RLYB (Rallybio Corporation)|lexariabioscience.com (LEXX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio PULM (Pulmatrix Inc)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pheton Holdings Limited|Company Value to EBITDA Aptorum APM|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lyra Therapeutics, Inc. (LYRA)|IBO (impactbiomedinc.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple TNFA (TNF Pharmaceuticals, Inc.)|EV/EBITDA Multiple cbdMD Inc. YCBD|PRFX: Enterprise Value to EBITDA Ratio|Altamira Therapeutics - Enterprise Value to Operating Income Before Depreciation Ratio|LIPO: EV/EBITDA Multiple|OPTN - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pieris Pharmaceuticals, Inc.|Company Value to EBITDA Procaps Group PROC|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Petros (PTPI)|Qilian International Corp - Enterprise Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Acelyrin, Inc. SLRN|tffpharma.com - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
